Radiation dosimetry and biodistribution of the TSPO ligand 11C-DPA-713 in humans

Christopher J. Endres, Jennifer Marie Coughlin, Kenneth L. Gage, Crystal Watkins, Michael Kassiou, Martin Gilbert Pomper

Research output: Contribution to journalArticle

Abstract

Whole-body PET/CT was used to characterize the radiation dosimetry of 11C-DPA-713, a specific PET ligand for the assessment of translocator protein. Methods: Six healthy control subjects, 3 men and 3 women, underwent whole-body dynamic PET scans after bolus injection of 11C-DPA-713. Subjects were scanned from head to mid thigh with 7 passes performed, with a total PET acquisition of approximately 100 min. Time-activity curves were generated in organs with visible tracer uptake, and tissue residence times were calculated. Whole-body dosimetry was calculated using OLINDA 1.1 software, assuming no voiding. Results: The absorbed dose is highest in the lungs, spleen, kidney, and pancreas. The lungs were determined to be the dose-limiting organ, with an average absorbed dose of 2.01 ×10 -2 mSv/MBq (7.43 × 10 -2 rem/mCi). On the basis of exposure limits outlined in the U.S. Food and Drug Administration Code of Federal Regulations (21CFR361.1), the single-dose limit for 11C-DPA-713 radiotracer injection is 2,487.6 MBq (67.3 mCi). Conclusion: 11C-DPA-713 has an uptake pattern that is consistent with the biodistribution of translocator protein and yields a dose burden that is comparable to that of other 11C-labeled PET tracers.

Original languageEnglish (US)
Pages (from-to)330-335
Number of pages6
JournalJournal of Nuclear Medicine
Volume53
Issue number2
DOIs
StatePublished - Feb 1 2012

Fingerprint

Radiometry
Ligands
Lung
Injections
United States Food and Drug Administration
Thigh
Positron-Emission Tomography
Pancreas
Healthy Volunteers
Proteins
Software
Spleen
Head
Kidney
N,N-diethyl-2-(2-(4-methoxyphenyl)-5,7-dimethyl-pyrazolo(1,5-a)pyrimidin-3-yl)-acetamide

Keywords

  • Dosimetry
  • Microglia
  • PET/CT
  • Radiotracer tissue kinetics
  • Translocator protein

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Radiation dosimetry and biodistribution of the TSPO ligand 11C-DPA-713 in humans. / Endres, Christopher J.; Coughlin, Jennifer Marie; Gage, Kenneth L.; Watkins, Crystal; Kassiou, Michael; Pomper, Martin Gilbert.

In: Journal of Nuclear Medicine, Vol. 53, No. 2, 01.02.2012, p. 330-335.

Research output: Contribution to journalArticle

@article{5b3425eec73843d783f19479f57637e3,
title = "Radiation dosimetry and biodistribution of the TSPO ligand 11C-DPA-713 in humans",
abstract = "Whole-body PET/CT was used to characterize the radiation dosimetry of 11C-DPA-713, a specific PET ligand for the assessment of translocator protein. Methods: Six healthy control subjects, 3 men and 3 women, underwent whole-body dynamic PET scans after bolus injection of 11C-DPA-713. Subjects were scanned from head to mid thigh with 7 passes performed, with a total PET acquisition of approximately 100 min. Time-activity curves were generated in organs with visible tracer uptake, and tissue residence times were calculated. Whole-body dosimetry was calculated using OLINDA 1.1 software, assuming no voiding. Results: The absorbed dose is highest in the lungs, spleen, kidney, and pancreas. The lungs were determined to be the dose-limiting organ, with an average absorbed dose of 2.01 ×10 -2 mSv/MBq (7.43 × 10 -2 rem/mCi). On the basis of exposure limits outlined in the U.S. Food and Drug Administration Code of Federal Regulations (21CFR361.1), the single-dose limit for 11C-DPA-713 radiotracer injection is 2,487.6 MBq (67.3 mCi). Conclusion: 11C-DPA-713 has an uptake pattern that is consistent with the biodistribution of translocator protein and yields a dose burden that is comparable to that of other 11C-labeled PET tracers.",
keywords = "Dosimetry, Microglia, PET/CT, Radiotracer tissue kinetics, Translocator protein",
author = "Endres, {Christopher J.} and Coughlin, {Jennifer Marie} and Gage, {Kenneth L.} and Crystal Watkins and Michael Kassiou and Pomper, {Martin Gilbert}",
year = "2012",
month = "2",
day = "1",
doi = "10.2967/jnumed.111.094565",
language = "English (US)",
volume = "53",
pages = "330--335",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "2",

}

TY - JOUR

T1 - Radiation dosimetry and biodistribution of the TSPO ligand 11C-DPA-713 in humans

AU - Endres, Christopher J.

AU - Coughlin, Jennifer Marie

AU - Gage, Kenneth L.

AU - Watkins, Crystal

AU - Kassiou, Michael

AU - Pomper, Martin Gilbert

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Whole-body PET/CT was used to characterize the radiation dosimetry of 11C-DPA-713, a specific PET ligand for the assessment of translocator protein. Methods: Six healthy control subjects, 3 men and 3 women, underwent whole-body dynamic PET scans after bolus injection of 11C-DPA-713. Subjects were scanned from head to mid thigh with 7 passes performed, with a total PET acquisition of approximately 100 min. Time-activity curves were generated in organs with visible tracer uptake, and tissue residence times were calculated. Whole-body dosimetry was calculated using OLINDA 1.1 software, assuming no voiding. Results: The absorbed dose is highest in the lungs, spleen, kidney, and pancreas. The lungs were determined to be the dose-limiting organ, with an average absorbed dose of 2.01 ×10 -2 mSv/MBq (7.43 × 10 -2 rem/mCi). On the basis of exposure limits outlined in the U.S. Food and Drug Administration Code of Federal Regulations (21CFR361.1), the single-dose limit for 11C-DPA-713 radiotracer injection is 2,487.6 MBq (67.3 mCi). Conclusion: 11C-DPA-713 has an uptake pattern that is consistent with the biodistribution of translocator protein and yields a dose burden that is comparable to that of other 11C-labeled PET tracers.

AB - Whole-body PET/CT was used to characterize the radiation dosimetry of 11C-DPA-713, a specific PET ligand for the assessment of translocator protein. Methods: Six healthy control subjects, 3 men and 3 women, underwent whole-body dynamic PET scans after bolus injection of 11C-DPA-713. Subjects were scanned from head to mid thigh with 7 passes performed, with a total PET acquisition of approximately 100 min. Time-activity curves were generated in organs with visible tracer uptake, and tissue residence times were calculated. Whole-body dosimetry was calculated using OLINDA 1.1 software, assuming no voiding. Results: The absorbed dose is highest in the lungs, spleen, kidney, and pancreas. The lungs were determined to be the dose-limiting organ, with an average absorbed dose of 2.01 ×10 -2 mSv/MBq (7.43 × 10 -2 rem/mCi). On the basis of exposure limits outlined in the U.S. Food and Drug Administration Code of Federal Regulations (21CFR361.1), the single-dose limit for 11C-DPA-713 radiotracer injection is 2,487.6 MBq (67.3 mCi). Conclusion: 11C-DPA-713 has an uptake pattern that is consistent with the biodistribution of translocator protein and yields a dose burden that is comparable to that of other 11C-labeled PET tracers.

KW - Dosimetry

KW - Microglia

KW - PET/CT

KW - Radiotracer tissue kinetics

KW - Translocator protein

UR - http://www.scopus.com/inward/record.url?scp=84856806258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856806258&partnerID=8YFLogxK

U2 - 10.2967/jnumed.111.094565

DO - 10.2967/jnumed.111.094565

M3 - Article

C2 - 22241913

AN - SCOPUS:84856806258

VL - 53

SP - 330

EP - 335

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 2

ER -